vs
Side-by-side financial comparison of Powerfleet, Inc. (AIOT) and Amphastar Pharmaceuticals, Inc. (AMPH). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $113.5M, roughly 1.6× Powerfleet, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -3.0%, a 16.3% gap on every dollar of revenue. On growth, Powerfleet, Inc. posted the faster year-over-year revenue change (6.6% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $4.9M). Over the past eight quarters, Powerfleet, Inc.'s revenue compounded faster (81.2% CAGR vs 3.2%).
Powerfleet, Inc. is an American company headquartered in Woodcliff Lake, New Jersey, that operates as a global provider of IoT and M2M solutions for securing, controlling, and tracking high-value enterprise assets. The company is a provider in the international telematics industry, providing fleet management, asset tracking, freight visibility, and driver behavior monitoring for industrial trucks, vehicle fleets, and shipping containers.
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AIOT vs AMPH — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $113.5M | $183.1M |
| Net Profit | $-3.4M | $24.4M |
| Gross Margin | 55.2% | 46.8% |
| Operating Margin | 5.6% | 19.4% |
| Net Margin | -3.0% | 13.3% |
| Revenue YoY | 6.6% | -1.8% |
| Net Profit YoY | 76.6% | -35.7% |
| EPS (diluted) | $-0.03 | $0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $113.5M | $183.1M | ||
| Q3 25 | $111.7M | $191.8M | ||
| Q2 25 | $104.1M | $174.4M | ||
| Q1 25 | $103.6M | $170.5M | ||
| Q4 24 | $106.4M | $186.5M | ||
| Q3 24 | $77.0M | $191.2M | ||
| Q2 24 | $75.4M | $182.4M | ||
| Q1 24 | — | $171.8M |
| Q4 25 | $-3.4M | $24.4M | ||
| Q3 25 | $-4.3M | $17.4M | ||
| Q2 25 | $-10.2M | $31.0M | ||
| Q1 25 | $-12.4M | $25.3M | ||
| Q4 24 | $-14.3M | $38.0M | ||
| Q3 24 | $-1.9M | $40.4M | ||
| Q2 24 | $-22.3M | $37.9M | ||
| Q1 24 | — | $43.2M |
| Q4 25 | 55.2% | 46.8% | ||
| Q3 25 | 56.0% | 51.4% | ||
| Q2 25 | 54.2% | 49.6% | ||
| Q1 25 | 52.8% | 50.0% | ||
| Q4 24 | 55.2% | 46.5% | ||
| Q3 24 | 53.7% | 53.3% | ||
| Q2 24 | 52.6% | 52.2% | ||
| Q1 24 | — | 52.4% |
| Q4 25 | 5.6% | 19.4% | ||
| Q3 25 | 3.8% | 13.2% | ||
| Q2 25 | -2.0% | 24.2% | ||
| Q1 25 | -6.7% | 21.9% | ||
| Q4 24 | -1.2% | 24.2% | ||
| Q3 24 | 0.7% | 29.8% | ||
| Q2 24 | -24.2% | 30.3% | ||
| Q1 24 | — | 27.9% |
| Q4 25 | -3.0% | 13.3% | ||
| Q3 25 | -3.8% | 9.0% | ||
| Q2 25 | -9.8% | 17.8% | ||
| Q1 25 | -12.0% | 14.8% | ||
| Q4 24 | -13.5% | 20.4% | ||
| Q3 24 | -2.5% | 21.1% | ||
| Q2 24 | -29.6% | 20.8% | ||
| Q1 24 | — | 25.1% |
| Q4 25 | $-0.03 | $0.51 | ||
| Q3 25 | $-0.03 | $0.37 | ||
| Q2 25 | $-0.08 | $0.64 | ||
| Q1 25 | $-0.09 | $0.51 | ||
| Q4 24 | $-0.11 | $0.74 | ||
| Q3 24 | $-0.02 | $0.78 | ||
| Q2 24 | $-0.21 | $0.73 | ||
| Q1 24 | — | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.2M | $282.8M |
| Total DebtLower is stronger | $237.8M | $608.7M |
| Stockholders' EquityBook value | $485.0M | $788.8M |
| Total Assets | $959.5M | $1.6B |
| Debt / EquityLower = less leverage | 0.49× | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.2M | $282.8M | ||
| Q3 25 | $27.9M | $276.2M | ||
| Q2 25 | $31.2M | $231.8M | ||
| Q1 25 | $44.4M | $236.9M | ||
| Q4 24 | $33.6M | $221.6M | ||
| Q3 24 | $26.0M | $250.5M | ||
| Q2 24 | $30.2M | $217.8M | ||
| Q1 24 | — | $289.6M |
| Q4 25 | $237.8M | $608.7M | ||
| Q3 25 | $238.2M | $608.6M | ||
| Q2 25 | $239.0M | $607.7M | ||
| Q1 25 | $237.5M | $603.9M | ||
| Q4 24 | $238.5M | $601.6M | ||
| Q3 24 | $113.6M | $596.4M | ||
| Q2 24 | $113.7M | $586.9M | ||
| Q1 24 | — | $594.0M |
| Q4 25 | $485.0M | $788.8M | ||
| Q3 25 | $468.8M | $776.7M | ||
| Q2 25 | $460.7M | $757.5M | ||
| Q1 25 | $446.6M | $751.3M | ||
| Q4 24 | $458.4M | $732.3M | ||
| Q3 24 | $451.0M | $727.7M | ||
| Q2 24 | $390.4M | $713.3M | ||
| Q1 24 | — | $672.4M |
| Q4 25 | $959.5M | $1.6B | ||
| Q3 25 | $936.9M | $1.7B | ||
| Q2 25 | $930.8M | $1.6B | ||
| Q1 25 | $910.1M | $1.6B | ||
| Q4 24 | $908.7M | $1.6B | ||
| Q3 24 | $748.3M | $1.5B | ||
| Q2 24 | $684.9M | $1.5B | ||
| Q1 24 | — | $1.6B |
| Q4 25 | 0.49× | 0.77× | ||
| Q3 25 | 0.51× | 0.78× | ||
| Q2 25 | 0.52× | 0.80× | ||
| Q1 25 | 0.53× | 0.80× | ||
| Q4 24 | 0.52× | 0.82× | ||
| Q3 24 | 0.25× | 0.82× | ||
| Q2 24 | 0.29× | 0.82× | ||
| Q1 24 | — | 0.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.2M | $32.9M |
| Free Cash FlowOCF − Capex | $4.9M | $24.6M |
| FCF MarginFCF / Revenue | 4.4% | 13.4% |
| Capex IntensityCapex / Revenue | 4.6% | 4.5% |
| Cash ConversionOCF / Net Profit | — | 1.35× |
| TTM Free Cash FlowTrailing 4 quarters | $12.9M | $121.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.2M | $32.9M | ||
| Q3 25 | $5.5M | $52.6M | ||
| Q2 25 | $4.7M | $35.6M | ||
| Q1 25 | $13.5M | $35.1M | ||
| Q4 24 | $-6.1M | $29.0M | ||
| Q3 24 | $-3.2M | $60.0M | ||
| Q2 24 | $-7.6M | $69.1M | ||
| Q1 24 | — | $55.3M |
| Q4 25 | $4.9M | $24.6M | ||
| Q3 25 | $1.2M | $47.2M | ||
| Q2 25 | $-3.4M | $25.0M | ||
| Q1 25 | $10.1M | $24.4M | ||
| Q4 24 | $-12.2M | $16.6M | ||
| Q3 24 | $-8.0M | $46.2M | ||
| Q2 24 | $-13.2M | $63.1M | ||
| Q1 24 | — | $46.5M |
| Q4 25 | 4.4% | 13.4% | ||
| Q3 25 | 1.1% | 24.6% | ||
| Q2 25 | -3.3% | 14.3% | ||
| Q1 25 | 9.8% | 14.3% | ||
| Q4 24 | -11.5% | 8.9% | ||
| Q3 24 | -10.4% | 24.1% | ||
| Q2 24 | -17.5% | 34.6% | ||
| Q1 24 | — | 27.1% |
| Q4 25 | 4.6% | 4.5% | ||
| Q3 25 | 3.9% | 2.8% | ||
| Q2 25 | 7.8% | 6.1% | ||
| Q1 25 | 3.3% | 6.3% | ||
| Q4 24 | 5.8% | 6.7% | ||
| Q3 24 | 6.3% | 7.2% | ||
| Q2 24 | 7.4% | 3.3% | ||
| Q1 24 | — | 5.1% |
| Q4 25 | — | 1.35× | ||
| Q3 25 | — | 3.03× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | — | 1.39× | ||
| Q4 24 | — | 0.76× | ||
| Q3 24 | — | 1.48× | ||
| Q2 24 | — | 1.82× | ||
| Q1 24 | — | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIOT
| Services | $91.1M | 80% |
| Products | $22.4M | 20% |
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
